课题基金 / 基金详情

Gyrate Atrophy Ocular and Systemic Study (GYROS)

Gyrate Atrophy Ocular and Systemic Study (GYROS)
回旋萎缩眼部和全身研究 (GYROS)
批准号:
10573885
负责人:
Allison Renee Ayala
金额:
$40.0万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-09-15 至 2027-08-31

项目摘要

项目成果

Allison Renee Ayala的其他基金

相似基金

相关文献

中文摘要
翻译
1陀螺仪项目摘要/摘要 2回状萎缩是一种罕见的遗传性脉络膜视网膜变性,与 3鸟氨酸转氨酶常染色体隐性突变引起的高鸟氨酸血症 4(燕麦)基因,导致严重失明。目前的护理治疗标准是 5高负担的精氨酸限制饮食(ARD),充满管理并发症。这个 主要研究人员目前正在开发一种基因增强疗法,一种潜在的 7治疗策略,可保护或改善视力,同时避免或减少 8需要ARD。为了促进未来的介入临床试验,有必要确定 9燕麦片相关眼部和全身疾病进展的自然病史。研究的目的是: 自然历史--描述鸟氨酸水平和视网膜的自然历史 11存在与致病燕麦变异体相关的变性(RD) 超过4年的12种标准饮食治疗方案,使用禁食的代谢措施 13个血浆和血斑氨基酸面板,RD的功能和结构措施, 14和患者报告的结果衡量标准。 15.代谢-结构-功能关系--探索 16结构性和功能性RD结局指标和血浆鸟氨酸水平。 17.识别快速进展因素--探索可能的风险因素之间的关系 18(基因、表型、环境、标准护理饮食方案)严重程度和 19成果衡量标准的进展情况。 20这项自然历史研究将为未来的介入临床试验设计提供如下信息: 21测定患者体内鸟氨酸水平的变异性 22开发了保存的视网膜区域进展的定量测量和 23确定其可重复性、对变化的敏感性以及与其他措施的关系 24建立功能性RD、结构性RD和患者报告的进展率 25个结果指标,并确定哪些指标对变化最敏感 26确定计划的未来治疗试验的主要时间点和持续时间 27在试验样本量计算中使用结果的可变性和眼间相关性 28确定未来试验的候选人,包括基于风险因素的资格标准 29和最有可能从治疗中受益的疾病严重程度的分界点 30建立研究程序和工作流程
英文摘要
1 Project Summary/Abstract for GYROS 2 Gyrate atrophy is a rare inherited chorioretinal degeneration that is associated with 3 hyperornithinemia caused by autosomal recessive mutations in the ornithine aminotransferase 4 (OAT) gene and leads to severe loss of vision. The current standard of care treatment is a 5 highly burdensome arginine-restricted diet (ARD) fraught with management complications. The 6 principal investigators are currently developing a gene augmentation therapy, a potential 7 treatment strategy that may preserve or improve vision while avoiding or reducing the 8 need for ARD. To facilitate a future interventional clinical trial, there is a need to characterize 9 the natural history of OAT-related ocular and systemic disease progression. The study aims are: 10 1. Natural History – Characterize the natural history of ornithine levels and retinal 11 degeneration (RD) associated with disease-causing OAT variants in the presence of 12 standard dietary treatment regimens over 4 years, using metabolic measures of fasting 13 plasma and blood spot amino acids panels, functional and structural measures of RD, 14 and patient-reported outcome measures. 15 2. Metabolic-Structure-Function Relationships – Explore the relationships between 16 structural and functional RD outcome measures and plasma ornithine levels. 17 3. Identify Rapid Progressors – Explore the relationship of possible risk factors 18 (genotype, phenotype, environmental, standard care dietary regimen) with severity and 19 progression of outcome measures. 20 This natural history study will inform the future interventional clinical trial design as follows: 21  Determine within-patient variability of ornithine levels 22  Develop quantitative measures of progression of the area of preserved retina and 23 establish its reproducibility, sensitivity to change, and relationship with other measures 24  Establish rates of progression of functional RD, structural RD, and patient-reported 25 outcome measures, and determine which measures are most sensitive to change 26  Determine primary time points and duration for a planned future treatment trial 27  Use variability and inter-eye correlation of outcomes for trial sample size calculations 28  Identify candidates for the future trial, including eligibility criteria based on risk factors 29 and cut points for severity of disease most likely to benefit from treatment 30  Establish study procedures and workflows
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Safety and Feasibility of Cultivated Autologous Limbal Epithelial Cell (CALEC) Transplantation in the Treatment of Limbal Stem Cell Deficiency
Effect of Corneal Preservation Time on Long-Term Graft Success (CPTS)
Effect of Corneal Preservation Time on Long-Term Graft Success (CPTS)
Effect of Corneal Preservation Time on Long-Term Graft Success (CPTS)
海外基金